UNSPSC 51283609: Rifamycin o

This classification denotes an antitubercular agent with the molecular formula C39H47NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z67LEM9P1W, chemically known as 4-o-(carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxorifamycin .gamma.-lactone, but more generally known as rifamycin o, which bears US NIH Compound Identifier 5280468. European Medicines Agency schedules rifamycin o or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG.

Most nations, for tariff purposes, schedule rifamycin o under HS 29419000. SMILES: CC1C(C2C3C4C1O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)NC(=CC35OCC(=O)O5)C2=O)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.

UNSPSC 51283609 Rifamycin o is a Commodity code for a specific pharmaceutical active ingredient; state and local procurement activity under this code shows minimal recent solicitation volume and a significant mismatch between the code's nominal scope and the work actually being bought. The recent opportunities tagged to this code involve broad pharmaceutical procurement (antibiotics like Doxycycline and Ciprofloxacin, naloxone, and drug deactivation systems) rather than rifamycin specifically, suggesting that state and local procurement offices are either tagging opportunities at a higher taxonomic level or using the code as a catch-all for pharmaceutical acquisitions without precision to the specific active ingredient. State and local buyers under pharmaceutical codes include state health departments, county health systems, and regional public-health authorities.

The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 (award completed, not an open solicitation) for antibiotic tablets supplied through a consortium purchasing vehicle, while Seminole County, Florida issued an IFB on June 30, 2026 for naloxone and drug deactivation systems with quarterly deliveries to a county health building (response deadline July 26, 2023 — note: this deadline is in the past and the opportunity appears expired). Geographic activity is scattered across Florida and Illinois with no clear concentration. The code shows little targeted procurement activity specific to rifamycin itself; buyers pursuing pharmaceutical supply contracts should verify code assignment with the issuing procurement office before investing in proposal development, as tagging precision under this Commodity code appears inconsistent with actual category scope.